XeriSol: A Biocompatible, Non-Aqueous Approach to Enhanced Peptide Solubility and Stability
Steven Prestrelski
Founder and Chief Scientific Officer, Xeris Pharmaceuticals
Peptide drug formulations are prone to degradation and aggregation/fibrillation in aqueous environments. Our proprietary XeriSol™ non-aqueous formulation technology platform is designed to address the limitations of aqueous formulations for peptide drugs. The solutions are formulated using biocompatible, non-aqueous solvents that have high stability and solubility. The solvent prevents degradation and aggregation/fibrillation of the peptide and allows for development of room-temperature stable, ready-to-use peptide formulations. When a ready-to-use XeriSol formulation is injected into a patient, it is effectively placed back into a water environment where it displays high bioavailability. This presentation will showcase the technology platform including clinical data from the Gvoke® (glucagon injection) product which has been approved and is being commercialized globally. In addition, results will be presented for a pramlintide-insulin co-formulation currently in clinical studies.
Dr. Prestrelski is the Founder and Chief Scientific Officer of Xeris Pharmaceuticals. He is also the inventor of the Xeris platform technologies. Dr. Prestrelski is an internationally recognized expert in drug formulation and delivery, with over 25 years of product development experience. Prior to joining Xeris, Dr. Prestrelski was Vice President of Pharmaceutical R&D at Amylin Pharmaceuticals. Previously, he was the Executive Director of the Bydureon® program at Amylin, leading this program from Phase 2 through global regulatory filings. Prior to Amylin, Dr. Prestrelski was Vice President, Biopharmaceuticals at PowderJect Technologies, Inc. where he pioneered the delivery of solid biopharmaceuticals. Dr. Prestrelski has also worked with Alza and Amgen in technical and management roles.